Article Text

Download PDFPDF

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
  1. Boris Minev1,2,
  2. Holbrook Kohrt3,
  3. Mehmet Kilinc2,
  4. Nanhai Chen2,
  5. Audrey Feng2,
  6. Maysam Pessian2,
  7. Ulrike Geissinger2,
  8. Erik Haefner4,
  9. Desislava Tsoneva4,
  10. Kliment Bozhilov5,
  11. Idit Sagiv-Barfi3,
  12. Xing Zhao3,
  13. Narendiran Rajesekaran3,
  14. Ronald Levy3 and
  15. Aladar Szalay2
  1. Aff1 grid.266100.30000000121074242University of California San Diego San Diego CA USA
  2. Aff2 grid.466735.5Genelux Corporation San Diego CA USA
  3. Aff3 grid.168010.e0000000419368956Stanford University Stanford CA USA
  4. Aff4 grid.8379.50000000119588658University of Wurzburg Germany
  5. Aff5 grid.162346.40000000114821895University of Hawaii HI USA

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Oncolytic virotherapy is safe and clinically active in solid tumors, however its efficacy in hematologic malignancies as well as in combination with checkpoint inhibitors and radiation is unexplored. To simulate advanced lymphoma, A20 cells were injected subcutaneously on bilateral flanks of BALB/c mice and treatment initiated on day 17 to only the right flank tumor with local irradiation (Irr), intratumoral (i.t.) vaccinia virus (VACV) and i.t. anti-CTLA-4 mAb (Irr-VACV-CTLA4, Figure 1). The Irr-VACV-CTLA4 regimen was the most effective in eradicating or shrinking both treated and untreated tumors and extending survival, followed by the Irr-VACV regimen. Treatment with Irr-VACV-CTLA4, led to initially a mature, activated NK cell (KLRG1+CD27+) infiltrate (day 6 post-treatment) followed by a CD8+T cells infiltrate (day+13) in treated tumors. In contrast, treatment with VACV-CTLA4 led to activated NK cell accumulation (day +6) followed by a CD8+ T cell infiltrate (day+13) in non-treated tumors. Importantly, CD8+CD44hi T cells isolated from the blood and spleens of the treated mice showed functional specificity to A20 lymphoma cells, but not to MHC-matched tumor cells (CT26) in intra-cellular stains for IFN-γ. Splenocyte-derived A20-specific CD8+CD44hi T cells were induced most efficiently in the Irr-VACV-CTLA4 regimen-treated mice, while blood-derived A20-specific CD8+CD44hi T cells were induced most efficiently in the Irr-VACV regimen-treated mice. Viral plaque assays (VPA) showed lack of live viral particles in both treated and untreated tumors upon sacrificing mice 4 to 10 weeks after treatment initiation. Surprisingly, VPA assays identified live virus in the livers of Irr-VACV-CTLA4 regimen-treated mice, which paralleled a reduced metastatic load.

Our findings are the first to demonstrate the potential of combination immunotherapy with oncolytic viruses and checkpoint inhibitors in hematologic malignancies. The antitumor activity is attributed to the induction of an effective and specific immune response. This finding is corroborated by the significant infiltration with mature activated NK cells, followed by CD8+ T cells, in both treated and untreated tumors. Importantly, the tumor-specific CD8+ T cells showing a memory phenotype (CD44hi) suggest the effective induction of a potent immune memory response. Effective targeting of distant metastases after intratumoral administration is also an important finding with significant clinical implications. This novel combination immunotherapy with oncolytic viruses and checkpoint inhibitors following local tumor irradiation is now being translated to a Phase I proof-of-concept clinical trial in non-Hodgkin's lymphoma at our institution.